Literature DB >> 24269594

Human induced pluripotent stem cells in hepatology: beyond the proof of concept.

Sabine Gerbal-Chaloin1, Natalie Funakoshi2, Amandine Caillaud3, Claire Gondeau1, Benoite Champon3, Karim Si-Tayeb4.   

Abstract

The discovery of the wide plasticity of most cell types means that it is now possible to produce virtually any cell type in vitro. This concept, developed because of the possibility of reprogramming somatic cells toward induced pluripotent stem cells, provides the opportunity to produce specialized cells that harbor multiple phenotypical traits, thus integrating genetic interindividual variability. The field of hepatology has exploited this concept, and hepatocyte-like cells can now be differentiated from induced pluripotent stem cells. This review discusses the choice of somatic cells to be reprogrammed by emergent new and nonintegrative strategies, as well as the application of differentiated human induced pluripotent stem cells in hepatology, including liver development, disease modeling, host-pathogen interactions, and drug metabolism and toxicity. The actual consensus is that hepatocyte-like cells generated in vitro present an immature phenotype. Currently, developed strategies used to resolve this problem, such as overexpression of transcription factors, mimicking liver neonatal and postnatal modifications, and re-creating the three-dimensional hepatocyte environment in vitro and in vivo, are also discussed.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24269594     DOI: 10.1016/j.ajpath.2013.09.026

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

Review 1.  Current strategies to generate mature human induced pluripotent stem cells derived cholangiocytes and future applications.

Authors:  Eduardo Cervantes-Alvarez; Yang Wang; Alexandra Collin de l'Hortet; Jorge Guzman-Lepe; Jiye Zhu; Kazuki Takeishi
Journal:  Organogenesis       Date:  2017-01-05       Impact factor: 2.500

Review 2.  A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms.

Authors:  A S Khazali; A M Clark; A Wells
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

3.  Hepatic regenerative medicine: exploiting the liver's will to live.

Authors:  Satdarshan P S Monga
Journal:  Am J Pathol       Date:  2014-02       Impact factor: 4.307

Review 4.  Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-05       Impact factor: 5.187

Review 5.  Stem cell-derived liver cells for drug testing and disease modeling.

Authors:  Matthew D Davidson; Brenton R Ware; Salman R Khetani
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

6.  A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells.

Authors:  Kota Tsuruya; Hiromi Chikada; Kinuyo Ida; Kazuya Anzai; Tatehiro Kagawa; Yutaka Inagaki; Tetsuya Mine; Akihide Kamiya
Journal:  Stem Cells Dev       Date:  2015-04-28       Impact factor: 3.272

Review 7.  Biofabrication of Autologous Human Hepatocytes for Transplantation: How Do We Get There?

Authors:  Nandini Agarwal; Branimir Popovic; Nicole J Martucci; Nicolas A Fraunhoffer; Alejandro Soto-Gutierrez
Journal:  Gene Expr       Date:  2018-08-24

Review 8.  Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury.

Authors:  Winfried Krueger; Urs A Boelsterli; Theodore P Rasmussen
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

9.  Human induced hepatic lineage-oriented stem cells: autonomous specification of human iPS cells toward hepatocyte-like cells without any exogenous differentiation factors.

Authors:  Tetsuya Ishikawa; Momoko Kobayashi; Satoshi Yanagi; Chika Kato; Ryokichi Takashima; Eiji Kobayashi; Keitaro Hagiwara; Takahiro Ochiya
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

10.  Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.

Authors:  Mariam Jouni; Karim Si-Tayeb; Zeineb Es-Salah-Lamoureux; Xenia Latypova; Benoite Champon; Amandine Caillaud; Anais Rungoat; Flavien Charpentier; Gildas Loussouarn; Isabelle Baró; Kazem Zibara; Patricia Lemarchand; Nathalie Gaborit
Journal:  J Am Heart Assoc       Date:  2015-09-01       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.